Rationale, discovery and clinical development of NEO-201
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...